A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B

A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol

OBJECTIVE To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients. PATIENTS AND METHODS A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monothera...

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

BACKGROUND In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. METHODS We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) d...

efficacy of pegylated interferon in treatment-experienced chinese patients with hbeag positive chronic hepatitis b

background after treatment cessation, a high prevalence of relapse was reported in chronic hepatitis b (chb) patients in china, especially in nucleot(s)ide analogues (nucs)-experienced patients. re-treatment for these patients remains unsolved. objectives this study aims to evaluate the efficacy of pegylated interferon in hbeag positive patients with exposure to antiviral therapy. patients and ...

Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Objective. To determine the efficacy and safety of Lingmao Formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase (ALT). Methods. 301 patients were randomly assigned to receive Lingmao Formula combined with entecavir (treatment group) or placebo combined with entecavir (control group) for 52 weeks. The outcomes of interest i...

The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment.